ArticleMolecular cancer therapeutics2019
Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 36% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.CNS oncology · 2026Pooled it
- Cut the fat: targeting cholesterol and lipid metabolism in glioblastoma.Cell death & disease · 2025Review
- Unraveling the mechanisms of glioblastoma's resistance: investigating the influence of tumor suppressor p53 and non-coding RNAs.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- The Impact of Metabolic Rewiring in Glioblastoma: The Immune Landscape and Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Proton pump inhibitors are detrimental to overall survival of patients with glioblastoma: Results from a nationwide real-world evidence database.Neuro-oncology practice · 2024Article
- Article
- A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Targeting Oncogenic Rewiring of Lipid Metabolism for Glioblastoma Treatment.International journal of molecular sciences · 2022Review
- TRPM7 Induces Tumorigenesis and Stemness Through Notch Activation in Glioma.Frontiers in pharmacology · 2020Article
- EGFR amplification status for clinical trial inclusion: where do we draw the line?Neuro-oncology · 2019Article
- Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 6 institutions in 3 countries.
Andrew McKinneyDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Olle R LindbergDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-5646-2501
Jane R EnglerDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Katharine Y ChenDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Anupam KumarDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Henry GongDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Kan V LuDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Erin F SimondsDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-3497-4861
Timothy F CloughesyUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Linda M LiauUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-4053-0052
Michael PradosDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Andrew W BollenDepartment of Pathology, Division of Neuropathology, University of California, San Francisco, San Francisco, California.
Mitchel S BergerDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Joseph T C ShiehDivision of Medical Genetics, Department of Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, San Francisco, California.
C David JamesNeurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Theodore P NicolaidesDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
William H YongDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Albert LaiUCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Monika E HegiNeuroscience Research Center and Service of Neurosurgery, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-0855-6495
William A WeissDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California.
Joanna J PhillipsDepartment of Neurological Surgery, Brain Tumor Center, University of California, San Francisco, San Francisco, California. Joanna.phillips@ucsf.edu.
Neurological Surgery · USUniversity of California, San Francisco · USUniversity of California, Los Angeles · USNorthwestern University · USUCSF Benioff Children's Hospital · USUniversity of Lausanne · CH
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7MTissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2MSTINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Pouya Jamshidi · 2018 to 2026
$21.4MExtracellular Sulfatases As Novel Biomarkers For Early Detection of CancerU01CA168878 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEMJABBAR-ALAOUI, HASSAN, PHILLIPS, JOANNA · 2012 to 2016
$2.2MMitigation of preanalytic factors influencing brain tumor protein phosphorylationU01CA229345 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, JOANNA · 2019 to 2023
$1.8MHeparan sulfate proteoglycans as critical regulators of brain cancer malignancyR01NS081117 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PHILLIPS, JOANNA · 2012 to 2016
$1.7MInvestigation of tumor suppressive miR-148a in IDH mutant gliomasR01CA179071 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAI, ALBERT · 2014 to 2018
$1.6MNCI NIH HHS P30 CA082103NCI NIH HHS P50 CA097257NCI NIH HHS P50 CA211015NCI NIH HHS P50 CA221747NCI NIH HHS R01 CA179071NCI NIH HHS U01 CA168878NCI NIH HHS U01 CA229345NINDS NIH HHS R01 NS081117
Abstract
Amplification of the epidermal growth factor receptor gene (
Indexed as
Aldehyde Dehydrogenase 1 FamilyAnimalsBrain NeoplasmsCell Line, TumorCell ProliferationDasatinibDrug Resistance, NeoplasmErbB ReceptorsErlotinib HydrochlorideGlioblastomaHumansMiceOxidative StressProtein Kinase InhibitorsRetinal DehydrogenaseXenograft Model Antitumor AssaysAldehyde Dehydrogenase 1 FamilyALDH1A1 protein, humanDasatinibEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideProtein Kinase InhibitorsRetinal Dehydrogenase
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.